2. Academic Validation
  3. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

  • Hepatology. 2007 Oct;46(4):1041-8. doi: 10.1002/hep.21800.
Byung Chul Yoo 1,  Ju Hyun Kim,  Tae-Hun Kim,  Kwang Cheol Koh,  Soon-Ho Um,  Young Soo Kim,  Kwan Sik Lee,  Byung Hoon Han,  Chae Yoon Chon,  Joon-Yeol Han,  Soo Hyung Ryu,  Haak Cheoul Kim,  Kwan Soo Byun,  Seong Gyu Hwang,  Byung-Ik Kim,  Mong Cho,  Kwon Yoo,  Heon-Ju Lee,  Jae Seok Hwang,  Yun Soo Kim,  Young-Suk Lee,  Sung-Kyu Choi,  Youn-Jae Lee,  Jin-Mo Yang,  Joong-Won Park,  Myung-Seok Lee,  Dae-Ghon Kim,  Young-Hwa Chung,  Se-Hyun Cho,  Jong-Young Choi,  Young-Oh Kweon,  Heon Young Lee,  Sook-Hyang Jeong,  Hee-Won Yoo,  Hyo-Suk Lee
Affiliations

Affiliation

  • 1 Sungkyunkwan University Samsung Medical Center, Seoul, South Korea.
PMID: 17647293 DOI: 10.1002/hep.21800
Abstract

Clevudine is a pyrimidine analog with potent and sustained Antiviral activity against HBV. In the present study, we evaluated the safety and efficacy of clevudine 30 mg daily for 24 weeks and assessed the durability of Antiviral response for 24 weeks after cessation of dosing in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (e-CHB). We randomized a total of 86 patients (3:1) to receive clevudine 30 mg (n = 63) or placebo (n = 23) daily for 24 weeks. We followed patients for an additional 24 weeks after withdrawal of treatment. The median changes in HBV DNA from baseline were -4.25 and -0.48 log(10) copies/mL at week 24 in the clevudine and placebo groups, respectively (P < 0.0001). Viral suppression in the clevudine group was sustained after withdrawal of therapy, with 3.11 log(10) reduction at week 48. At week 24 and week 48, 92.1% and 16.4% of patients in the clevudine group had undetectable serum HBV DNA levels by Amplicor PCR assay (<300 copies/mL). The proportion of patients who achieved ALT normalization was 74.6% and 33.3% in the clevudine and placebo groups at week 24, respectively (P = 0.0006). ALT normalization in the clevudine group was well-maintained during the post-treatment follow-up period. The incidence of adverse events was similar in the 2 groups. No resistance to clevudine was detected during treatment.

Conclusion: A 24-week clevudine therapy was well-tolerated and showed potent and sustained Antiviral effect without evidence of viral resistance in e-CHB patients. However, treatment for longer than 24 weeks would be needed to achieve durable remission.

Figures
Products